Clinical Commander

Back to dossier
cardio.atrial_flutter.with-stroke.v1PRODUCTION
cardio.atrial_flutter.with-stroke.v1

Atrial flutter complicated by acute embolic stroke

cardiologyacuteadult
Hard-required inputs
0 / 15
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Acute ischemic stroke + atrial flutter (new or known) — composite cardioembolic stroke event. Two parallel decisions: (1) acute reperfusion (tPA / TNK / thrombectomy) — same as non-AFL stroke; (2) AC restart timing — withhold 1–14 d per infarct size, NO LMWH bridging — AHA/ASA 2024 (PMID 38483443)

Inputs
3
Actions
0
Advance rule
Set
Advance when

Composite stroke + flutter confirmed

Patient inputs (15)

MRI/DWI quantifies infarct volume — drives AC-delay window (small 1–3 d, medium 6–7 d, large 10–14 d) per AHA/ASA 2024 + ELAN (PMID 37162478)

TTE/TEE for cardiac source confirmation — LA appendage thrombus, EF, valve disease; TEE Class I for cryptogenic stroke

CHA2DS2-VASc + thrombolysis age cutoff considerations + frailty/bleed-risk for AC delay decision

Flutter RVR contributes to perfusion mismatch + cardiac demand; HR target 80–110 in stroke + flutter

tPA within 4.5 h of LKW; thrombectomy within 24 h with perfusion mismatch (DAWN/DEFUSE-3)

NIHSS drives thrombectomy eligibility (≥6) + AC-delay timing (mild <6 = early AC at d3; severe ≥16 = delay 10–14 d) — AHA/ASA 2024 (PMID 38483443)

STAT non-contrast CT head — rule out hemorrhage; ASPECTS for anterior circulation; required pre-tPA + thrombectomy decision (AHA/ASA 2024)

CTA head/neck for LVO + collateral assessment; drives mechanical thrombectomy decision (DAWN PMID 29129157, DEFUSE-3 PMID 29364767)

Confirm flutter morphology + rate; rule out concomitant AF; 30-d ambulatory monitoring if cryptogenic (CRYSTAL-AF)

Contrast for CTA + DOAC dose adjustment + tPA exclusion criteria (no specific renal cutoff for tPA)

Stroke mimic exclusion (hypoglycemia); pre-tPA glucose 50–400 mg/dL

tPA contraindicated if plt <100k, INR >1.7, PTT abnormal; baseline coags pre-AC restart

BP <185/110 required pre-tPA; permissive HTN in non-tPA candidates; SBP <90 with flutter RVR → DCCV

CHA2DS2-VASc — score is automatically ≥2 with prior stroke (Class I AC indication post-stroke)

HAS-BLED + prior intracranial bleed history may shift toward LAA occlusion (Watchman) instead of long-term AC

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateninghemorrhagic_conversion_of_infarct
    Worsening NIHSS + new headache/vomiting + STAT CT shows hemorrhagic conversion (PH-1 / PH-2) — life-threatening tPA complication
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningrecurrent_stroke_off_ac_during_delay_window
    Recurrent ischemic stroke during the AC delay window (1–14 d) — protection-vs-bleed dilemma
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningcerebral_edema_with_midline_shift
    Large hemispheric infarct with cerebral edema, midline shift, and clinical deterioration — malignant MCA syndrome
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningflutter_with_hemodynamic_instability_during_acute_stroke
    Atrial flutter with RVR + SBP <90 + lactate elevation during acute stroke window — perfusion mismatch worsens infarct
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecontraindication_to_ac_discovered
    Active GI bleed, new CNS bleed, severe thrombocytopenia, or other absolute AC contraindication identified during inpatient stay
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

Atrial flutter + acute embolic stroke — acute reperfusion + delayed-AC (1–14 d per infarct size, NO LMWH bridge) + long-term DOAC pathway — AHA/ASA 2024 (PMID 38483443) + ACC/AHA 2024 AF (PMID 38753446) + ELAN (PMID 37162478)
axis: aflutter_with_acute_stroke_ac_timing_pathway
Selected axis "Atrial flutter + acute embolic stroke — acute reperfusion + delayed-AC (1–14 d per infarct size, NO LMWH bridge) + long-term DOAC pathway — AHA/ASA 2024 (PMID 38483443) + ACC/AHA 2024 AF (PMID 38753446) + ELAN (PMID 37162478)" by default fallback (first axis)
  • alteplase
    first line
    tissue_plasminogen_activator
    0.9 mg/kg IV (max 90 mg); 10% bolus over 1 min then 90% over 60 min • IV • one-time
    triggers: stroke_within_4.5h_LKW, no_tPA_contraindication, NIHSS_>=4_or_disabling_deficit
    AHA/ASA 2024 Class I within 4.5 h (PMID 38483443); door-to-needle 45 min target
    rxcui 8410
  • tenecteplase
    first line
    tissue_plasminogen_activator
    0.25 mg/kg IV bolus (max 25 mg) • IV • one-time
    triggers: stroke_within_4.5h_LKW, LVO_pre_thrombectomy_transfer, no_tPA_contraindication
    EXTEND-IA TNK (PMID 29694815) — non-inferior to alteplase, single bolus; AHA/ASA 2024 reasonable alternative
    rxcui 259280
  • unfractionated_heparin
    rescue
    heparin
    NO ROUTINE BRIDGING — only for mechanical valve / LV thrombus + small infarct + low bleed risk; if used: 60 U/kg bolus then 12 U/kg/h to PTT 1.5–2× control • IV • bolus + infusion (case-by-case only)
    triggers: mechanical_valve_with_small_infarct, LV_thrombus_with_small_infarct_LOW_bleed_risk
    AHA/ASA 2024 — bridging with LMWH NOT recommended (PMID 38483443); UFH only in select high-thrombotic-risk + low-bleed situations
    rxcui 5224
  • metoprolol_tartrate
    first line
    beta_blocker
    5 mg IV q5min × 3 then 25–50 mg PO BID • IV/PO • IV q5min × 3 → PO BID
    triggers: flutter_RVR_with_stroke, no_HFrEF_decompensation
    AVN slowing for flutter; permissive HR control to support cerebral perfusion — ACC/AHA 2024 (PMID 38753446)
    rxcui 203191
  • apixaban
    first line
    DOAC_factor_Xa
    5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) — START AT DAY: small infarct (<1.5 cm) d1–3; medium infarct d6–7; large infarct (>3 cm or NIHSS ≥16) d10–14 • PO • BID
    triggers: post_stroke_AC_window, CHA2DS2VASc_>=2_post_stroke
    AHA/ASA 2024 (PMID 38483443) — DOAC preferred; ELAN (PMID 37162478) supports early initiation d3–4 for minor/moderate; ARISTOTLE foundational (PMID 21870978)
    rxcui 1364430
  • rivaroxaban
    first line
    DOAC_factor_Xa
    20 mg with food (15 mg if CrCl 15–50) — START per infarct-size delay window • PO • once daily
    triggers: post_stroke_AC_window, apixaban_unavailable
    ROCKET-AF (PMID 21830957); same delay-window approach
    rxcui 1114195
  • dabigatran
    first line
    DOAC_direct_thrombin
    150 mg BID (110 mg BID if ≥80 yr or higher bleed risk, where approved); avoid CrCl <30 • PO • BID
    triggers: post_stroke_AC_window, idarucizumab_reversal_preference
    RE-LY (PMID 19717844) — idarucizumab available for emergent reversal
    rxcui 1037045
  • edoxaban
    first line
    DOAC_factor_Xa
    60 mg daily (30 mg if CrCl 15–50, ≤60 kg, or P-gp inhibitor); avoid CrCl >95 • PO • once daily
    triggers: post_stroke_AC_window, CrCl_50-95
    ENGAGE-AF-TIMI-48 (PMID 24251369)
    rxcui 1599538
  • warfarin
    comorbidity specific
    vitamin_K_antagonist
    5 mg daily; INR target 2–3 • PO • daily
    triggers: mechanical_valve, severe_mitral_stenosis, DOAC_contraindicated, severe_renal_failure_CrCl_<15
    Mechanical valve / severe MS → only warfarin; renal failure DOAC-ineligible — ACC/AHA 2024 (PMID 38753446)
    rxcui 11289
  • atorvastatin
    first line
    statin
    80 mg PO daily (high-intensity) • PO • daily
    triggers: ischemic_stroke_secondary_prevention
    AHA/ASA 2024 Class I high-intensity statin for ischemic stroke; LDL <70 target (PMID 38483443)
    rxcui 83367

outpatient playbook — drug actions (3)

  1. 1. continue DOAC lifelong
    rxcui 1364430
    apixaban 5 mg BID per CHA2DS2-VASc + dose-reduction criteria • PO • BID
    trigger: Lifelong stroke prevention
    AHA/ASA 2024 Class I + ARISTOTLE (PMID 21870978)
  2. 2. continue atorvastatin 80
    rxcui 83367
    80 mg PO daily; target LDL <70 • PO • daily
    trigger: Secondary prevention
    AHA/ASA 2024 Class I
  3. 3. wean rate control if successful CTI ablation
    rxcui 866427
    taper metoprolol over 4–8 weeks if no recurrence at 3 mo • PO • taper
    trigger: Successful ablation + no recurrence
    ACC/AHA 2024

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Acute focal neuro deficit (NIHSS-scored) in patient with known or new atrial flutter — cardioembolic stroke until proven otherwise; CTA-confirmed LVO + atrial flutter on monitor → emergent thrombectomy + delayed AC; Atrial flutter newly diagnosed on telemetry / extended monitoring during stroke workup — cardioembolic etiology.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Atrial flutter complicated by acute embolic stroke** (cardio.atrial_flutter.with-stroke.v1).
Scope: Acute ischemic stroke + atrial flutter (new or known) — composite cardioembolic stroke event. Two parallel decisions: (1) acute reperfusion (tPA / TNK / thrombectomy) — same as non-AFL stroke; (2) AC restart timing — withhold 1–14 d per infarct size, NO LMWH bridging — AHA/ASA 2024 (PMID 38483443)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Atrial flutter + acute embolic stroke — acute reperfusion + delayed-AC (1–14 d per infarct size, NO LMWH bridge) + long-term DOAC pathway — AHA/ASA 2024 (PMID 38483443) + ACC/AHA 2024 AF (PMID 38753446) + ELAN (PMID 37162478)**.
1. alteplase 0.9 mg/kg IV (max 90 mg); 10% bolus over 1 min then 90% over 60 min IV one-time (tissue_plasminogen_activator, first line) — AHA/ASA 2024 Class I within 4.5 h (PMID 38483443); door-to-needle 45 min target
2. tenecteplase 0.25 mg/kg IV bolus (max 25 mg) IV one-time (tissue_plasminogen_activator, first line) — EXTEND-IA TNK (PMID 29694815) — non-inferior to alteplase, single bolus; AHA/ASA 2024 reasonable alternative
3. unfractionated_heparin NO ROUTINE BRIDGING — only for mechanical valve / LV thrombus + small infarct + low bleed risk; if used: 60 U/kg bolus then 12 U/kg/h to PTT 1.5–2× control IV bolus + infusion (case-by-case only) (heparin, rescue) — AHA/ASA 2024 — bridging with LMWH NOT recommended (PMID 38483443); UFH only in select high-thrombotic-risk + low-bleed situations
4. metoprolol_tartrate 5 mg IV q5min × 3 then 25–50 mg PO BID IV/PO IV q5min × 3 → PO BID (beta_blocker, first line) — AVN slowing for flutter; permissive HR control to support cerebral perfusion — ACC/AHA 2024 (PMID 38753446)
5. apixaban 5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) — START AT DAY: small infarct (<1.5 cm) d1–3; medium infarct d6–7; large infarct (>3 cm or NIHSS ≥16) d10–14 PO BID (DOAC_factor_Xa, first line) — AHA/ASA 2024 (PMID 38483443) — DOAC preferred; ELAN (PMID 37162478) supports early initiation d3–4 for minor/moderate; ARISTOTLE foundational (PMID 21870978)
6. rivaroxaban 20 mg with food (15 mg if CrCl 15–50) — START per infarct-size delay window PO once daily (DOAC_factor_Xa, first line) — ROCKET-AF (PMID 21830957); same delay-window approach
7. dabigatran 150 mg BID (110 mg BID if ≥80 yr or higher bleed risk, where approved); avoid CrCl <30 PO BID (DOAC_direct_thrombin, first line) — RE-LY (PMID 19717844) — idarucizumab available for emergent reversal
8. edoxaban 60 mg daily (30 mg if CrCl 15–50, ≤60 kg, or P-gp inhibitor); avoid CrCl >95 PO once daily (DOAC_factor_Xa, first line) — ENGAGE-AF-TIMI-48 (PMID 24251369)
9. warfarin 5 mg daily; INR target 2–3 PO daily (vitamin_K_antagonist, comorbidity specific) — Mechanical valve / severe MS → only warfarin; renal failure DOAC-ineligible — ACC/AHA 2024 (PMID 38753446)
10. atorvastatin 80 mg PO daily (high-intensity) PO daily (statin, first line) — AHA/ASA 2024 Class I high-intensity statin for ischemic stroke; LDL <70 target (PMID 38483443)

Setting playbook (outpatient) — Long-term secondary stroke prevention + flutter management; lifelong DOAC; CTI ablation if typical flutter; LDL <70; BP <130/80; cardiac rehab; routing to cardio.atrial_flutter.typical-cavotricuspid.v1 or atypical variant per ECG morphology — AHA/ASA 2024 + ACC/AHA 2024
11. continue DOAC lifelong apixaban 5 mg BID per CHA2DS2-VASc + dose-reduction criteria PO BID — Lifelong stroke prevention (AHA/ASA 2024 Class I + ARISTOTLE (PMID 21870978))
12. continue atorvastatin 80 80 mg PO daily; target LDL <70 PO daily — Secondary prevention (AHA/ASA 2024 Class I)
13. wean rate control if successful CTI ablation taper metoprolol over 4–8 weeks if no recurrence at 3 mo PO taper — Successful ablation + no recurrence (ACC/AHA 2024)

Non-pharmacologic actions:
- Cardiac + stroke rehab maintenance (AHA/ASA 2024)
- Lifestyle: BP, weight, alcohol, OSA, exercise (AHA/ASA 2024 + ACC/AHA 2024)
- LAA occlusion (Watchman) consideration if AC contraindicated long-term — ACC/AHA 2024

AVOID / contraindication checks:
- TPA contraindicated if recent surgery 2wk or GIB 3wk or prior ICH — AHA/ASA 2024 (PMID 38483443)
- LMWH bridging NOT recommended post stroke — AHA/ASA 2024 Class III (PMID 38483443)
- AC delay tier by infarct size — AHA/ASA 2024 (small 1 3d, medium 6 7d, large 10 14d)
- DOAC renal dose adjustment — ESC 2024 (PMID 39050851)
- Warfarin only if mechanical valve or severe MS — ACC/AHA 2024 (PMID 38753446)
- Dabigatran avoid CrCl <30 — drug label
- Repeat CT at 24h pre AC restart — AHA/ASA 2024

Monitoring

Regimen monitoring:
- NIHSS q15min x 2h then q30min x 6h then q1h x 24h post tPA — AHA/ASA 2024
- BP <180/105 x 24h post tPA then <140/90 — AHA/ASA 2024
- repeat CT head at 24h pre AC restart — AHA/ASA 2024 (PMID 38483443)
- telemetry continuous for flutter recurrence — ACC/AHA 2024
- INR q week during warfarin initiation if used — standard
- CBC + eGFR q6m on DOAC — ESC 2024 (PMID 39050851)
- lifelong AC for secondary stroke prevention — AHA/ASA 2024 Class I

Setting (outpatient) monitoring:
- Quarterly clinic + annual EF + lipid (AHA/ASA 2024)
- CBC + eGFR q6m on DOAC (ESC 2024)
- Holter at 6 + 12 mo post-ablation for recurrence (Calkins 2007)

Follow-up plan: Stroke clinic + cardiology + EP for flutter ablation candidacy; ambulatory ECG monitoring if cryptogenic; LDL <70 + statin; BP <130/80; cardiac rehab; long-term DOAC lifelong (CHA2DS2-VASc ≥2)
- Close-out criterion: Follow-up booked + secondary prevention bundle started

Monitoring phase: 24-h post-tPA NIHSS q15min × 2h then q30min × 6h then q1h; repeat CT at 24 h before AC restart; daily neuro exam; telemetry for flutter; BP target <180/105 post-tPA × 24 h then <140/90

Disposition

Current setting: outpatient — Long-term secondary stroke prevention + flutter management; lifelong DOAC; CTI ablation if typical flutter; LDL <70; BP <130/80; cardiac rehab; routing to cardio.atrial_flutter.typical-cavotricuspid.v1 or atypical variant per ECG morphology — AHA/ASA 2024 + ACC/AHA 2024

Disposition criteria:
- Continue chronic surveillance; cross-link to cardio.atrial_flutter.typical-cavotricuspid.v1 if typical morphology + ablation pathway

Escalation triggers (move to higher acuity):
- Recurrent stroke / TIA on AC → re-evaluate, consider LAA occlusion or agent switch (AHA/ASA 2024)
- Major bleed on AC → hold + reverse + reassess long-term strategy
- New AF detected — same AC strategy (already on); expedite ablation if symptomatic

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Worsening NIHSS + new headache/vomiting + STAT CT shows hemorrhagic conversion (PH-1 / PH-2) — life-threatening tPA complication
- [LIFE_THREATENING] Recurrent ischemic stroke during the AC delay window (1–14 d) — protection-vs-bleed dilemma
- [LIFE_THREATENING] Large hemispheric infarct with cerebral edema, midline shift, and clinical deterioration — malignant MCA syndrome

Citations

- 2024 AHA/ASA Acute Ischemic Stroke Guideline (Greenberg PMID 38483443) + 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) [PMID:38483443](https://pubmed.ncbi.nlm.nih.gov/38483443/)
- Cited evidence (PMID 38753446) [PMID:38753446](https://pubmed.ncbi.nlm.nih.gov/38753446/)
- Cited evidence (PMID 39050851) [PMID:39050851](https://pubmed.ncbi.nlm.nih.gov/39050851/)
- Cited evidence (PMID 37162478) [PMID:37162478](https://pubmed.ncbi.nlm.nih.gov/37162478/)
- Cited evidence (PMID 19717844) [PMID:19717844](https://pubmed.ncbi.nlm.nih.gov/19717844/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2024 AHA/ASA Acute Ischemic Stroke Guideline (Greenberg PMID 38483443) + 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) — PMID:38483443
  • Cited evidence (PMID 38753446) — PMID:38753446
  • Cited evidence (PMID 39050851) — PMID:39050851
  • Cited evidence (PMID 37162478) — PMID:37162478
  • Cited evidence (PMID 19717844) — PMID:19717844